Consensus InnovAge Holding Corp.

Equities

INNV

US45784A1043

Market Closed - Nasdaq 04:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
4 USD -0.74% Intraday chart for InnovAge Holding Corp. -2.20% -33.33%

Evolution of the average Target Price on InnovAge Holding Corp.

Price target over the last 5 years

History of analyst recommendation changes

68fbe2e6cf5.yqJQQRqDtyIf-p0rKVKElWba3Ta-1E7NDaS8v35FmSA.re8xOVnO_UtereVscDvq31aclkTt4R-CbvXTxkkU7BaTzjQlftnVWzK8-g~8da060bc675720e1175e1ec67c6badbe
JPMorgan Adjusts Price Target on InnovAge to $6 From $7, Maintains Neutral Rating MT
Goldman Sachs Trims Price Target on InnovAge Holding to $7 From $8, Maintains Neutral Rating MT
JPMorgan Adjusts InnovAge Price Target to $7 From $8, Maintains Neutral Rating MT
MORNING BID AMERICAS-Risk and rates moving in tandem RE
Goldman Sachs Adjusts Price Target on InnovAge Holding to $9 From $8, Maintains Neutral Rating MT
JPMorgan Raises InnovAge Holding's Price Target to $8 From $5, Maintains Neutral Rating MT
Goldman Sachs Adjusts InnovAge Holding's Price Target to $8 From $6, Keeps Neutral Rating MT
Citigroup Adjusts Price Target on InnovAge Holding to $8 From $5, Maintains Neutral Rating MT
Barclays Adjusts Price Target on InnovAge to $5 From $6, Keeps Equalweight Rating MT
Baird Downgrades InnovAge to Neutral From Outperform, Adjusts Price Target to $5 From $6 MT
Piper Sandler Lwoers InnovAge Holding's Price Target to $3.90 From $5, Underweight Rating Kept MT
Piper Sandler Downgrades InnovAge to Underweight From Neutral, Adjusts Price Target to $5 From $4 MT
Goldman Sachs Cuts InnovAge to Neutral From Buy, Price Target to $4 From $15 MT
JPMorgan Lowers Price Target for InnovAge Holding to $6 From $10, Maintains Neutral Rating MT
Barclays Lowers InnovAge to Equalweight From Overweight, Price Target to $6.50 From $22 MT
Baird Adjusts Price Target on InnovAge Holding to $11 From $22, Maintains Outperform Rating MT
Piper Sandler Downgrades InnovAge to Neutral From Overweight, Adjusts Price Target to $4 From $14 MT
JPMorgan Starts InnovAge at Neutral With $10 Price Target MT
Piper Sandler Adjusts Price Target on InnovAge to $14 From $20, Reiterates Overweight Rating MT
INNOVAGE : Citigroup Downgrades InnovAge Holding to Neutral From Buy MT
ANALYST RECOMMENDATIONS : Amgen, Apple, AstraZeneca, FedEx, T-Mobile US... Our Logo
INNOVAGE : Cowen Adjusts Price Target for InnovAge Holding to $13 From $17, Maintains Market Perform Rating MT
INNOVAGE : Goldman Sachs Adjusts Price Target for InnovAge Holding to $17 From $28, Maintains Buy Rating MT
INNOVAGE : William Blair Downgrades InnovAge Holding to Market Perform from Outperform, Adjusts Price Target to $8.91 From $20.77 MT
INNOVAGE : Cowen Starts InnovAge Holding at Market Perform with $17 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
4 USD
Average target price
6.5 USD
Spread / Average Target
+62.50%
High Price Target
7 USD
Spread / Highest target
+75.00%
Low Price Target
6 USD
Spread / Lowest Target
+50.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering InnovAge Holding Corp.

JPMorgan Chase
Goldman Sachs
Citigroup
Barclays
Baird
Piper Sandler
William Blair & Co.
Cowen
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock Market
  2. Equities
  3. INNV Stock
  4. Consensus InnovAge Holding Corp.